A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Myositis
Active Idiopathic Inflammatory Myopathy
Dermatomyositis
Polymyositis
Immune-Mediated Necrotizing Myopathy
Antisynthetase Syndrome

Interventions

BIOLOGICAL: Efgartigimod PH20 SC

Sponsor

argenx